右旋布洛芬治疗幼年特发性关节炎患儿的疗效观察

doi:10.3969/j.issn.1671-7171.2022.03.015

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1131 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨右旋布洛芬治疗幼年特发性关节炎(JIA)患儿的疗效、安全性及对血清中致痛介质、炎症因子表达的影响。【方法】在本院就诊的JIA患儿84例,随机分为对照组和观察组,每组各42例。对照组给予萘普生治疗,观察组给予右旋布洛芬治疗,均持续治疗2周。对比两组临床疗效,采用幼年关节炎疾病活动性评分表(JADAS27)评定患儿治疗前后临床症状及体征改善情况,并分析治疗前后血清中致痛介质[5-羟色胺(5-HT)、前列腺素E₂(PGE₂)、缓激肽(BK)、神经肽Y(NPY)]及炎症因子[肿瘤坏死因子-α(TNF-α)、白介素1(IL-1)、白介素17(IL-17)、基质金属蛋白酶-3(MMP-3)]表达水平的变化,比较两组不良反应发生率。【结果】观察组患儿治疗总有效率为85.71%(36/42),显著高于对照组的64.29%(27/42)(P<0.05)。两组患儿治疗后JADAS27各维度评分及总分均显著低于治疗前(均P<0.05),且观察组治疗后上述指标均显著低于对照组(均P<0.05)。两组患儿治疗后血清5-HT、PGE₂、BK、NPY及TNF-α、IL-1、IL-17、MMP-3水平均显著低于治疗前(均P<0.05),且观察组患儿治疗后上述指标均显著低于对照组(均P<0.05)。观察组患儿不良反应发生率为4.76%(2/42),显著低于对照组的19.05%(8/42)(P<0.05)。【结论】右旋布洛芬治疗JIA疗效显著,能够明显改善患儿的临床症状及体征,抑制炎症因子和致痛介质的表达,且安全性较好。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	赵苗苗
	张昆

关键词 ：关节炎, 青少年, 布洛芬/治疗应用, 治疗结果

Abstract：【Objective】To investigate the efficacy and safety of dexibuprofen in children with juvenile idiopathic arthritis (JIA) and the expression of serum pain mediators and inflammatory factors. 【Methods】A total of 84 patients with JRA in our hospital were selected as the research objects and they were randomly divided into two groups, with 42 cases in the control group and 42 cases in the observation group. The control group was treated with naproxen, while the study group was treated with dexibuprofen for 2 weeks. The juvenile arthritis disease activity scale (JADAS27) was used to assess the improvement of clinical symptoms and physical signs before and after treatment. The serum pain mediators [serotonin (5-HT) and prostaglandin E2 (PGE2), slow excitation peptide bradykinin (BK), neuropeptide Y (NPY)] and inflammatory factor [tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), interleukin 17 (IL-17), matrix metalloproteinases-3(MMP-3)] expression levels were compared between the two groups as well. The incidence of adverse reactions were also compared. 【Results】The total effective rate of the observation group was 85.71%, which was significantly higher than 64.29% of the control group (P<0.05). The scores of each dimension and total score of JADAS27 in the two groups after treatment were significantly lower than those before treatment (all P<0.05), and the above indexes in the observation group after treatment were significantly lower than those in the control group after treatment (all P<0.05). The serum levels of 5-HT, PGE2, BK, NPY, TNF-α, IL-1, IL-17 and MMP-3 in the two groups after treatment were significantly lower than those before treatment (all P<0.05), and the above indexes in the observation group were significantly lower than those in the control group (all P<0.05). The incidence of adverse reactions in the observation group was 4.76% (2/42), which was significantly lower than 19.05% (8/42) in the control group (P<0.05). 【Conclusion】The efficacy of dextral ibuprofen (dexibuprofen) in the treatment of JIA is remarkable, which can significantly improve the clinical symptoms and signs of children, inhibit the expression of inflammatory factors and pain-causing mediators, and has good safety.

Key words： Arthritis, Juvenile Ibuprofen/TU Treatment Outcome

收稿日期: 2021-06-17

中图分类号:

R452

通讯作者: * E-mail:3458622@qq.com

引用本文:

赵苗苗, 张昆. 右旋布洛芬治疗幼年特发性关节炎患儿的疗效观察[J]. 医学临床研究, 2022, 39(3): 374-377.
ZHAO Miao-miao, ZHANG Kun. Efficacy and Safety of Dexibuprofen in Children with Juvenile Idiopathic Arthritis. JOURNAL OF CLINICAL RESEARCH, 2022, 39(3): 374-377.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.03.015 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I3/374

[1] AESCHLIMANN F A,QUARTIER P. Juvenile idiopathic arthritis[J].Rev Prat,2019,69(2):188-194.
[2] 林基勇,庞宇舟,方刚,等. 基于GoPubMed类风湿关节炎发病机制的文献计量学分析[J].现代预防医学,2019,46(3):563-567.
[3] CIMAZ R,MAIOLI G,CLABRESE G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis[J].Expert Opin Biol Ther,2020,20(7):725-740.
[4] HALYABAR O,MEHTA J,RINGOLD S,et al. Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature[J].Paediatr Drugs,2019,21(6):469-492.
[5] PETTY R E,SOUTHWOOD T R,MANNERS P,et al. International league of associations for rheumatology classification of juvenile idiopathic arthritis: second revision,Edmonton,2001[J].J Rheumatol,2004,31(2):390-392.
[6] MOURÃO A F,SANTOS M J,MELO-GOMES J,et al. Using the juvenile arthritis disease activity score based on erythrocyte sedimentation rate or C-reactive protein level: results from the portuguese[J].Arthritis Care Res (Hoboken),2014,66(4):585-591.
[7] 刘蕾,封其华. 幼年特发性关节炎病情评估方法研究进展[J].中华实用儿科临床杂志,2019,34(19):1516-1520.
[8] TOMIOKA R B,FERREIRA G R V,AIKAWA N E,et al. Non-steroidal anti-inflammatory drug induces luteinized unruptured follicle syndrome in young female juvenile idiopathic arthritis patients[J].Clin Rheumatol,2018,37(10):2869-2873.
[9] JACOBSON J L,PHAM J T. Juvenile idiopathic arthritis: a focus on pharmacologic management[J].J Pediatr Health Care,2018,32(5):515-528.
[10] CHOI Y,MIN K A,KIM C K. Development and evaluation of dexibuprofen formulation with fast onset and prolonged effect[J].Drug Dev Ind Pharm,2019,45(6):895-904.
[11] OKAMOTO N,YOKOTA S,TAKEI S,et al. Clinical practice guidance for juvenile idiopathic arthritis (JIA) 2018[J].Mod Rheumatol,2019,29(1):41-59.
[12] 吴小川,李灿琳. 全身型幼年特发性关节炎发生机制及诊治策略[J].中华实用儿科临床杂志,2017,32(21):1607-1612.
[13] 谢彤,尹薇. 右旋布洛芬和萘普生在治疗儿童幼年特发性关节炎中的对照观察[J].中华实用儿科临床杂志,2020,35(21):1656-1658.